LUND, Sweden, Oct. 15, 2021 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), a diagnostic company that develops and sells
highly accurate blood tests for the early detection of cancer,
announced today that Karin Almqvist Liwendahl will join Immunovia
as Chief Financial Officer (CFO).
Karin is an experienced CFO and Investor Relations professional
with a background in the telecom industry and life sciences. Most
recently she has been the CFO of the medical technology company
Dignitana. She has also been Financial Advisor and CFO at Sprint
Bioscience and Interim CFO of Kontigo Care. Karin has 15 years'
experience from several senior positions within Telia including
Director, Corporate Treasury, Telia Company, CFO of Telia Carrier, Managing Director and Country
Manager of Telia Carrier in
Russia. She has also been Head of
Investor Relations at Ericsson between 1994 and 2000. Karin holds a
bachelor's degree from Lund University.
Current CFO Hans Liljenborg will
continue with Immunovia in the position as Finance Director.
"I am pleased to welcome Karin to our company. With her deep
experience of leading and developing finance functions and strong
background in Investor Relations, I am convinced that she will make
an important impact on our business. As we move forward, we need to
continue to strengthen our communications with the investor
community, nationally and internationally. I am also glad that Hans
will continue in a new role with Immunovia. In that way we will
secure continuity in our finance function", said Patrik Dahlen, CEO of Immunovia.
Karin will start her assignment at the latest by April 1st, 2022.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 13:30 CEST on October 15, 2021.
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com. The European
launch plan will be communicated during the second half of
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download: